Pirlimycin
WikiDoc Resources for Pirlimycin |
Articles |
---|
Most recent articles on Pirlimycin |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Pirlimycin at Clinical Trials.gov Clinical Trials on Pirlimycin at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Pirlimycin
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Pirlimycin Discussion groups on Pirlimycin Patient Handouts on Pirlimycin Directions to Hospitals Treating Pirlimycin Risk calculators and risk factors for Pirlimycin
|
Healthcare Provider Resources |
Causes & Risk Factors for Pirlimycin |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Pirlimycin hydrochloride belongs to the lincosamide class of antimicrobials. It is bacteriostatic and acts by inhibiting bacterial protein synthesis via binding with the 50S subunit of the ribosome. It is frequently used in the treatment of bovine mastitis caused by Gram-positive bacteria, specifically Staphylococcus aureus and coagulase negative species of Staphylococcus and Streptococcus. It has no activity against Gram-negative bacteria.